Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Apoptosis protection and survival signal by the CD53 tetraspanin antigen

Abstract

The CD53 antigen is a tetraspanin protein of the lymphoid–myeloid lineage, but its implication in biological effects is hardly known. Radioresistant tumor cells express very high levels of this antigen. We have studied the effect of CD53 antigen ligation on the survival response of tumor cells to serum deprivation, a well-known stimulator of cell death that may mimic the tumor environment; for this aim IR938F and Jurkat cells, a B- and T-cell lymphoma, were used. Ligation of CD53 triggers a survival response and reduces the number of cells that enter apoptosis. In CD53- stimulated cells there is a significant reduction in caspase activation, measured by caspase processing of poly ADP-ribose polymerase, as well as a reduction in the fragmentation of DNA. CD53- stimulated cells also have an increase in the level of bcl-XL and a reduction of bax protein, two components of the mitochondrial apoptotic pathway, changing their ratio by 24-fold in the direction of survival. This survival signal appears to be mediated by activation of the AKT, as detected by its phosphorylation in Ser473 upon CD53 ligation. The CD53 antigen interactions might contribute to cell survival in poorly vascularized regions of the tumor mass.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM . (2000). Nature, 403, 503–511.

  • Angelisova P, Vlcek C, Stefanova I, Lipoldova M and Horejsi V . (1990). Immunogenetics, 32, 281–285.

  • Barcia R, García-Vargas S, Bosca L and Lazo PA . (1996). Cell. Immunol., 169, 107–112.

  • Berditchevski F . (2001). J. Cell Sci., 114, 4143–4151.

  • Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thompson CB . (1993). Cell, 74, 597–608.

  • Boscá L and Lazo PA . (1994). J. Exp. Med., 179, 1119 1126.

  • Boucheix C and Rubinstein E . (2001). Cell. Mol. Life Sci., 58, 1189–1205.

  • Dong J, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC . (1995). Science, 268, 884–886.

  • Ferrer M, Yunta M and Lazo PA . (1998). Clin. Exp. Immunol., 113, 346–352.

  • Frisch SM and Ruoslahti E . (1997). Curr. Opin. Cell Biol., 9, 701–706.

  • Frisch SM and Screaton RA . (2001). Curr. Opin. Cell Biol., 13, 555–562.

  • Gottlieb TM, Leal JF, Seger R, Taya Y and Oren M . (2002). Oncogene, 21, 1299–1303.

  • Guo X, Friess H, Graber HU, Kashigawi M, Zimmerman A, Kore M and Buchler MW . (1996). Cancer Res., 56, 4876–4880.

  • Hemler ME . (2001). J. Cell Biol., 155, 1103–1108.

  • Henkel GW, McKercher SR and Maki RA . (2002). Int. Immunol., 14, 723–732.

  • Hernández-Torres J, Yunta M and Lazo PA . (2001). J. Biol. Chem., 276, 35405–35413.

  • Herr I and Debatin KM . (2001). Blood, 98, 2603–2614.

  • Higashiyama M, Doi O, Kodama K, Yokouchi H, Adachi M, Huang C, Taki T, Kasugai T, Ishiguro S, Nakamori S and Miyake M . (1997). Int. J. Cancer, 205–211.

  • Higashiyama M, Taki T, Ieki Y, Adachi M, Huang C, Koh T, Kodama K, Doi O and Miyake M . (1995). Cancer Res., 55, 6040–6044.

  • Huang CI, Kohno N, Ogawa E, Adachi M, Taki T and Miyake M . (1998). Am. J. Pathol., 153, 973–983.

  • Igney FH and Krammer PH . (2002). Nature Rev. Cancer, 2, 277–288.

  • Ikeyama S, Koyama M, Yamaoko M, Sasada R and Miyake M . (1993). J. Exp. Med., 177, 1231–1237.

  • Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN and Hay N . (1997). Genes Dev., 11, 701–713.

  • Lagaudriere-Gesbert C, La Naour F, Lebel-Binay S, Billard M, Lemichez E, Boquet P, Boucheix C, Conjeaud H and Rubinstein E . (1997). Cell. Immunol., 182, 105–112.

  • Lazo PA, Cuevas L, Gutierrez del Arroyo A and Orue E . (1997). Cell. Immunol., 178, 132–140.

  • Levy S, Todd SC and Maecker HT . (1998). Annu. Rev. Immunol., 16, 89–109.

  • Longhurst CM, Jacobs JD, White MM, Crossno Jr JT, Fitzgerald DA, Bao J, Fitzgerald TJ, Raghow R and Jennings LK . (2002). J. Biol. Chem, 277, 32445–32452.

  • Maecker HT, Todd SC and Levy S . (1997). FASEB J., 11, 428–442.

  • Masellis-Smith A, Jensen GS, Seehafer JG, Slupsky JR and Shaw ARE . (1990). J. Immunol., 144, 1607–1613.

  • Miyake M, Nakano K, Ieki Y, Adachi M, Huang C, Itoi S, Koh T and Taki T . (1995). Cancer Res., 55, 4127–4131.

  • Miyashita T, Krajewski S, Krajewski M, Wang HG, Lin HK, Lieberman DA, Hoffman B and Reed JC . (1994). Oncogene, 9, 1799–1805.

  • Mollinedo F, Fontán G, Barasoaín I and Lazo PA . (1997). Clin. Diag. Lab. Immunol., 4, 229–231.

  • Musashi M, Ota S and Shiroshita N . (2000). Int. J. Hematol., 72, 12–19.

  • Puls KL, Hogquist KA, Reilly N and Wright MD . (2002). Int Immunol, 14, 249–258.

  • Radford KJ, Mallesh J and Hersey P . (1995). Int. J. Cancer, 62, 631–635.

  • Scheid MP and Woodgett JR . (2001). Nat. Rev. Mol. Cell. Biol., 2, 760–768.

  • Shi Y . (2002). Mol. Cell, 9, 459–470.

  • Shibagaki N, Hanada K, Yamashita H, Shimada S and Hamada H . (1999). Eur. J. Immunol., 29, 4081–4091.

  • Stipp CS, Kolesnikova TV and Hemler ME . (2001). J. Biol. Chem., 276, 40545–40554.

  • Sugiura T and Berditchevski F . (1999). J. Cell Biol., 146, 1375–1389.

  • Testa JE, Brooks PC, Lin JM and Quigley JP . (1999). Cancer Res., 59, 3812–3820.

  • Travis GH, Sutcliffe JG and Bok D . (1991). Neuron, 6, 61–70.

  • Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M and Imamura M . (1999). Br. J. Cancer, 79, 1168–1173.

  • van Soest S, Westerveld A, de Jong PT, Bleeker-Wagemakers EM and Bergen AA . (1999). Surv. Ophthalmol., 43, 321–334.

  • Voehringer DW, Hirschberg DL, Xiao J, Lu Q, Roederer M, Lock CB, Herzenberg LA and Steinman L . (2000). Proc. Natl. Acad. Sci. USA, 97, 2680–2685.

  • Wang YD, De Vos J, Jourdan M, Couderc G, Lu ZY, Rossi JF and Klein B . (2002). Oncogene, 21, 2584–2592.

  • Yanez-Mo M, Alfranca A, Cabanas C, Marazuela M, Tejedor R, Ursa MA, Ashman LK, de Landazuri MO and Sanchez-Madrid F . (1998). J. Cell Biol., 141, 791–804.

  • Yunta M, Oliva JL, Barcia R, Horejsi V, Angelisova P and Lazo PA . (2002). Eur J. Biochem. 269, 1012–1021.

  • Zhang XA, Bontrager AL and Hemler ME . (2001). J. Biol. Chem. 276, 25005–25003.

Download references

Acknowledgements

This work was supported by grants from Ministerio de Ciencia y Tecnología (SAF2000/0169), Junta de Castilla y León (CSI1/01) and Fondo de Investigación Sanitaria (FIS-PI02-0585) to PAL.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pedro A Lazo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yunta, M., Lazo, P. Apoptosis protection and survival signal by the CD53 tetraspanin antigen. Oncogene 22, 1219–1224 (2003). https://doi.org/10.1038/sj.onc.1206183

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206183

Keywords

This article is cited by

Search

Quick links